Melanoma: Pathogenesis and Targeted Therapy.

MedComm (2020) · 2026 · PMC12765410 · PMID 41492362

Europe PMC DOI

hedged sentences

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

showed a trendp = 0.14not close (p > 0.1)

Furthermore, second interim analysis of IMspire150 showed a trend toward prolonged mOS in the atezolizumab group compared with the control group (39.0 vs. 25.8 months, p = 0.14) [ 22 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

2.4 years, p = 0.30), although the differences did not reach statistical significance [ 467 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.